The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial-Reference-Cited by-同舟云学术

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

Published:2021-01-25 Issue:4 Volume:23 Page:1020-1029
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

McEwan Phil¹^ORCID,Morgan Angharad R.¹,Boyce Rebecca¹,Bergenheim Klas²,Gause‐Nilsson Ingrid A.M.²,Bhatt Deepak L.³,Leiter Lawrence A.⁴^ORCID,Johansson Peter A.²,Mosenzon Ofri⁵^ORCID,Cahn Avivit⁵^ORCID,Wilding John P.H.⁶^ORCID

Affiliation:

1. Health Economics and Outcomes Research Ltd Cardiff UK

2. BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden

3. TIMI Study Group, Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA

4. Li Ka Shing Knowledge Institute, St Michael's Hospital University of Toronto Toronto Ontario Canada

5. Hadassah Medical Center, Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

6. University of Liverpool Liverpool UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14308

Reference61 articles.

1. International Diabetes Federation.IDF Diabetes Atlas ‐ 8th Edition.2017.https://diabetesatlas.org/resources/2017-atlas.html

2. Microvascular and Macrovascular Complications of Diabetes

3. Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit

4. The global burden of diabetes and its complications: an emerging pandemic

5. National Institute for Health and Care Excellence.Clinical guideline [NG28]: type 2 diabetes in adults: management.2017.https://www.nice.org.uk/guidance/ng28. (Accessed 25 August 2020).

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Impact of SGLT2 Inhibitors on Renal Function in Type 2 Diabetic Patients with Coronary Artery Disease Undergoing Percutaneous Intervention: A Systematic Review and Meta-Analysis;Current Diabetes Reviews;2024-07-03

3. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

4. Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis;Acta Diabetologica;2024-04-18

5. Exploring the Therapeutic Potential of Royal Jelly in Metabolic Disorders and Gastrointestinal Diseases;Nutrients;2024-01-29